Relay Therapeutics, Inc. (NASDAQ:RLAY) Chief Financial Officer Thomas Catinazzo has sold a total of $92,315 worth of company stock, according to a recent SEC filing. The transactions, which took place on July 29, 2024, involved shares sold at prices ranging from $8.22 to $8.85.
The filing indicated two separate sales transactions. In the first, Catinazzo sold 1,702 shares at a price of $8.85 per share, totaling approximately $15,062. The second transaction involved the sale of 9,078 shares at a weighted average price of $8.51, amounting to around $77,253. These sales were part of a prearranged trading plan under Rule 10b5-1, which allows insiders to sell shares at predetermined times to avoid accusations of trading on nonpublic information.
The transactions followed the vesting of restricted stock units (RSUs) on July 27, where a portion of the shares was sold to cover the reporting person's income tax withholding obligations. This sale was mandatory and conducted in accordance with the issuer's policies regarding the vesting of RSUs.
Following these transactions, Catinazzo's direct ownership in Relay Therapeutics includes 328,728 shares, which accounts for shares underlying RSUs as well. Relay Therapeutics, based in Cambridge, Massachusetts, specializes in biological products and is known for its innovative approach in the field of life sciences.
Investors and stakeholders of Relay Therapeutics may consider these transactions as part of their ongoing evaluation of the market and the company's stock performance.
In other recent news, Relay Therapeutics has experienced significant developments in its partnerships and stock ratings. The company's collaboration and license agreement with Roche's Genentech, which initially brought in $121.8 million, has been terminated. This decision impacts the future revenue potential of the SHP2 inhibitor, RLY-1971, and has led H.C. Wainwright to adjust its price target for Relay Therapeutics to $18.00 while maintaining a Buy rating.
In response to the company's first-quarter 2024 results, Oppenheimer has also adjusted its price target for Relay Therapeutics to $25 from $33, while maintaining an Outperform rating. Despite the delay in significant data availability until the end of 2024, the firm remains positive about Relay Therapeutics, particularly its lead drug candidate, RLY-2608.
On the other hand, Barclays has upgraded Relay Therapeutics' stock to Overweight from Equalweight, due to an improved outlook for the second half of 2024. The firm's decision was influenced by the potential impact of upcoming data updates in breast cancer research, which they believe present a favorable risk/reward scenario. These are the recent developments for Relay Therapeutics.
InvestingPro Insights
As Relay Therapeutics' CFO, Thomas Catinazzo, completes his recent stock sales, investors are keeping a close eye on the company's financial health and market performance. According to InvestingPro data, Relay Therapeutics has a market capitalization of approximately $1.1 billion. Despite the company's impressive revenue growth of 2873.65% over the last twelve months as of Q1 2024, it's important to note that Relay Therapeutics has reported a substantial gross profit margin deficit of -822.7% in the same period. This indicates that while the company's sales are increasing, the cost of goods sold is disproportionately high, leading to significant losses.
InvestingPro Tips reveal that Relay Therapeutics holds more cash than debt on its balance sheet, which is a positive sign for liquidity. However, the company is also quickly burning through cash and analysts do not anticipate it will be profitable this year. The stock price has experienced considerable volatility recently, with a strong return of 26.84% over the last month, yet year-to-date, the total return has been -24.89%. This suggests that while the company has had a recent upswing, the overall trend for the year has been negative.
For investors seeking a deeper dive into Relay Therapeutics' performance and potential, there are additional InvestingPro Tips available at https://www.investing.com/pro/RLAY. These insights could provide valuable context for understanding the company's strategic direction and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.